THERAPY DOSSIER · th-0320d988fe7b

Compound 48/80 (mast cell depletor) and a neurokinin 1 receptor antagonist

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25601496 ↗2015Reported benefit

Androctonus australis hector venom contributes to the interaction between neuropeptides and mast cells in pulmonary hyperresponsiveness.

MouseChemical/toxinMaleBefore venom administration (depletion and receptor blockade)

Model: Acute lung injury and pulmonary oedema induced by subcutaneous Androctonus australis hector scorpion venom

Pulmonary oedema measured by Evans blue extravasation was completely inhibited in compound 48/80 treated animals and the inflammatory response to venom was markedly reduced, indicating that mast cells acting through the neurokinin 1 receptor mediate venom-induced lung injury.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…